Urologie

[Urologie @Urologie]

Semi-Live • Heidelberg • 2024

https://t.co/YW6YST9zVJ

[Urologie @Urologie]

Semi-Live 2022 GLOBAL (March 2-5, 2022): Join wherever you are!
State of the Art in Urologic Surgery: View, discuss, reflect, contemplate, chat and earn CME's! Limitless due to opportunity!
Program and Registration: https://t.co/xsHbhsNPPs

https://t.co/aqCnabhAyh

[Urologie @Urologie]

Semi-Live 2022 GLOBAL (March 2-5, 2022): Join wherever you are!
State of the Art in Urologic Surgery: View, discuss, reflect, contemplate, chat and earn CME's! Limitless due to opportunity!
Program and Registration: https://t.co/xsHbhsNPPs

https://t.co/aqCnabhAyh

[Urologie @Urologie]

@iUrology
https://t.co/0buj95xxFw

[Urologie @Urologie]

@iUrology https://t.co/D9Wx8Ul36G

[Urology Heidelberg @Semi_Live]

Invitation to “Semi-Live 2022” in Heidelberg!
Registration is open! Early bird discount until December 15, 2021.
All info here: https://t.co/Uu6TgCEaWM

[Urology Heidelberg @Semi_Live]

Invitation to “Semi-Live 2022” in Heidelberg!
Registration is open! Early bird discount until December 15, 2021.
All info here: https://t.co/Uu6TgCEaWM

[Urologie @Urologie]

https://t.co/cUCILbsAvx

[Urologie @Urologie]

Semi-Live March 2022 in Heidelberg

[Urologie @Urologie]

State-of-the-art staging of high risk prostate cancer for subsequent local therapy: replacement of CT and bone scan by PSMA-PET.

https://t.co/O8pgJOM5rQ

[Urologie @Urologie]

Radiotherapy (RT) following radical prostatectomy: early salvage RT (PSA 0.2 ng/ml) vs.adjuvant RT reduces over-treatment by 50% with concomitant reduction of functional morbidities without compromising oncological safety.

https://t.co/SIwXVuPGaO

[Urologie @Urologie]

"Telephone": Multilateral Communication Management in Clinical Medicine

https://t.co/Osr1WbzxGW

[Urologie @Urologie]

Epigenetics of the fetal prostate and their association with metastatic prostate cancer

https://t.co/aJLc0CmLJ9

[Urologie @Urologie]

RAVES or the end of adjuvant radiotherapy in high-risk prostate cancer: early salvage radiotherapy +/- equally effective if delivered at a PSA of < / = 0.2.

PS: Indicate PSMA-PET in BCR!

https://t.co/ToIPLjHoNA

[Urologie @Urologie]

TREXIT?: Needle track seeding of prostate cancer after transrectal prostate biopsy.

https://t.co/fipw01EIik

[Urologie @Urologie]

RPx With vs. Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk PCa improved:

event-free (e.g. death, progression, additional treatment), metastatic free, & overall survival.

Did not improve 3-year biochemical progression-free survival.

https://t.co/ww3RWHEiIj

[Urologie @Urologie]

Die Urologie in Zeiten von Corona | Mit Prof. Dr. Markus Hohenfellner | ... https://t.co/L1zgDi5p2g via @YouTube

[Urologie @Urologie]

🍀‼️

https://t.co/uPa8MXmGpK

[Urologie @Urologie]

Precision oncology beats high-end standard care in Prostate Cancer:
https://t.co/LSA7Ea6yEq

[Urologie @Urologie]

DARULTAMIDE 4 NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER:
=> reduces the risk of death by 30%
=> vs. placebo comparable adverse events

https://t.co/yoIWOBXVkX

[Urologie @Urologie]

Similar pathways of compromized immunology in critical virus infections vs. critical cancers: a possible role of T cell - increased PD-1 expression. With a perspective of new indications for Checkpoint Inhibitors?

Sattler, Kotsch et al. (Charité 2020) https://t.co/HjMAwVnVbs